Endocardial fibroelastosis (EFE) is a cardiac pathology characterized by hypertrophy and fibrosis of the endocardial tissue, which impairs the functionality of the heart, especially its right chambers. This disease is most often observed in children, but it can also occur in adults. EFE manifests itself as cardiac insufficiency, arrhythmias, and can also be accompanied by signs of systemic failure and life-threatening conditions. One of the key features of EFE is its idiopathic nature, but in some cases it can develop against the background of other cardiac diseases or as a result of genetic disorders.
History of the disease and interesting historical facts
The first mention of endocardial fibroelastosis was made at the beginning of the 20th century. In 1958, American cardiologist D. Parkinson described this disease as a separate nosological unit, distinguishing it from a number of other cardiovascular pathologies. Interestingly, for decades the disease remained poorly studied, and only in the last 20-30 years data on its pathogenesis and clinical manifestations began to appear. In the 20th century, the use of echocardiography began to develop, which improved the diagnosis and monitoring of EFE.
Epidemiology
Endocardial fibroelastosis is a rare disease, its prevalence varies and is from 1 to 3 cases per 100,000 newborns. The total number of registered cases of EFE in children in the world varies in different countries, according to some studies, it reaches up to 5% among all cases of cardiopathies in children. In adults, statistics are less certain, but cases of EFE have also been registered, especially in combination with other cardiovascular diseases.
Genetic predisposition to this disease
To date, a number of genes have been studied that may be associated with the development of endocardial fibroelastosis. In particular, genes responsible for collagen metabolism, such as COL1A1 and COL1A2, have been identified. Mutations in these genes lead to disruption of the structure and function of connective tissues, which in turn can increase the risk of developing EFE. Other genetic markers and mutations that may be associated with a higher risk of the disease are also being studied.
Risk factors for the development of this disease
There are several factors that may increase your risk of developing endocardial fibroelastosis. These include:
- Heredity - the presence of cases of the disease in the family.
- Infectious diseases suffered by the mother during pregnancy.
- The influence of toxic substances and radiation.
- Chronic maternal diseases such as diabetes and hypertension.
- Hemodynamic disturbances in the fetus.
Diagnosis of this disease
Diagnosis of endocardial fibroelastosis requires a comprehensive approach, including clinical, laboratory and instrumental examination methods. The most pronounced symptoms of the disease may include:
- Shortness of breath, especially during physical exertion.
- Weakness and fatigue.
- Arrhythmias such as tachycardia or bradycardia.
- The most noticeable deviations in cardiac auscultation.
Important laboratory tests include blood tests to measure natriuretic peptide levels and echocardiography to visualize changes in the structure of the heart. In some cases, cardiac MRI or angiography may be required. Differential diagnosis includes ruling out other cardiac pathologies such as dilated cardiomyopathy and myocarditis.
Treatment
Treatment of endocardial fibroelastosis depends on the severity of the disease and may include both conservative and surgical methods. The main pharmacological treatment is aimed at improving heart function and includes:
- Diuretics to control edema and insufficiency.
- Beta blockers to regulate heart rhythm.
- ACE inhibitors to reduce the workload on the heart.
In some cases, surgical intervention may be considered, including operations to correct hemodynamic disturbances or replace damaged areas of the heart. More recently, physiotherapy methods have begun to be used in practice, such as rehabilitation of patients after cardiac surgery.
List of medications used to treat this disease
The following medications may be used to treat endocardial fibroelastosis:
- Furosemide (diuretic)
- Enalapril (ACE inhibitor)
- Metoprolol (beta blocker)
- Aspirin (antiplatelet agent)
- Digoxin (glycoside)
Disease monitoring
Monitoring endocardial fibroelastosis is important to prevent complications and prompt treatment. Regular screening includes:
- Echocardiography every 6-12 months to assess the dynamics of the heart condition.
- Cardiologist consultations – at least once a year.
- Monitoring of natriuretic peptide levels.
The safety prognosis for patients with EFE varies: in children with early onset or severe forms, morbidity and mortality remain high, but timely diagnosis and treatment can significantly improve quality of life. In adult patients, the outcome depends on the cause and associated pathologies.
Age-related features of the disease
In children, endocardial fibroelastosis is usually diagnosed at an early age and can have an aggressive course. In adults, the disease is less common, and its course is often associated with other cardiac pathologies. In the elderly, concomitant chronic diseases should be carefully considered, as they can worsen the condition and lead to a high risk of complications.
Questions and Answers
- What is endocardial fibroelastosis? This is a heart pathology characterized by hypertrophy and fibrosis of the endocardial tissue.
- What are the main symptoms of the disease? Shortness of breath, weakness, arrhythmia and heart failure.
- How is EFE diagnosed? Using echocardiography, blood analysis and other instrumental methods.
- How is endocardial fibroelastosis treated? Treatment may include conservative methods, such as drug therapy, and surgery.
- What is the prognosis for patients with EFE? The prognosis depends on the severity of the condition and associated diseases, but timely treatment can significantly improve the quality of life.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov emphasizes the importance of early diagnosis of endocardial fibroelastosis and respect for symptoms such as shortness of breath during physical exertion and frequent arrhythmias. “Timely intervention and regular examinations can significantly improve the patient’s quality of life,” he reminds. He also recommends paying attention to heredity and examining relatives if you have already had a case of EFE in your family. Regular health care and cardiovascular monitoring will help minimize the consequences of this disease.
